Cardio Diagnostics’ New $17M Common Stock Sales Agreement
Company Announcements

Cardio Diagnostics’ New $17M Common Stock Sales Agreement

Cardio Diagnostics Holdings (CDIO) has released an update to notify the public and investors about an entry into a material definitive agreement.

Cardio Diagnostics Holdings, Inc. entered into a Sales Agreement with Craig-Hallum Capital Group LLC to potentially sell up to $17 million in common stock at the company’s discretion. The agreement allows sales to be made through various market methods, with Craig-Hallum employing reasonable efforts to sell the shares according to specified terms. The company will pay a 2.5% commission on sales proceeds and reimburse certain legal costs, with the offering ending upon reaching the $17 million limit or Sales Agreement termination. The net proceeds are intended for general corporate purposes.

For further insights into CDIO stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TheFlyCardio Diagnostic’s Epi+Gen CHD test available at Meijer Supercenter
TheFlyCardio Diagnostics achieves SOC 2 Type I compliance certification
TheFlyCardio Diagnostics price target raised to $2 from $1.35 at Benchmark
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!